MedTrace Logo

Efficacy and Safety of Prednisolone and Chloroquine Add on Therapy in Osteoarthritis of the Knee

NCT00805519 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 230

Last updated 2010-04-30

No results posted yet for this study

Summary

This study was conducted to evaluate the efficacy and safety of prednisolone and chloroquine add on therapies to combined glucosamine, chondroitin sulfate in osteoarthritis of the knee which will be done in contrast to combined glucosamine sulfate and chondroitin.

Conditions

  • Osteoarthritis of the Knee

Interventions

DRUG

Glucosamine and chondroitin sulfate

In this arm fixed dose glucosamine (400 mg) and chondroitin sulfate (500 mg)combination will be administrated to the patients, daily.

DRUG

glucosamine and chondroitin sulfate plus Prednisolone

In this arm fixed dose glucosamine (400 mg) and chondroitin sulfate (500 mg)combination will be administrated to the patients as baseline therapy, daily. also,the patients will receive Prednisolone 5 mg/day

DRUG

Glucosamine and Chondroitin sulfate plus Chloroquine

In this arm fixed dose glucosamine (400 mg) and chondroitin sulfate (500 mg)combination will be administrated to the patients as baseline therapy, daily. also,the patients will receive chloroquine 150 mg every two days.

DRUG

Glucosamine,Chondroitin sulfate,Prednisolone,Chloroquine

In this arm fixed dose glucosamine (400 mg) and chondroitin sulfate (500 mg)combination will be administrated to the patients as baseline therapy, daily. also,the patients will receive prednisolone 5 mg/day and chloroquine 150 mg every two days.

Sponsors & Collaborators

  • Ardabil University of Medical Sciences

    lead OTHER

Principal Investigators

  • Shahab Bohlooli, PhD · Pharmacology Dept, Faculty of Medicine, ArdabilUMS

  • Marina Jastan, MD · Rheomatology clinic, Faculty of Medicine, ArdabilUMS

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2010-04-30
Completion
2010-04-30

Countries

  • Iran

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00805519 on ClinicalTrials.gov